Healthcare · Drug Manufacturers - Specialty & Generic · NASDAQ

Liquidia Technologies Inc (LQDA) Stock Price, Analysis & Trade Signals

$57.41-0.71 (-1.22%)

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North…

LQDA key stats

Market Cap
$5.17B
P/E Ratio
0
Forward P/E
13.79
EPS
-1.05
52 Week Range
$22.31 – $93.61
50-Day Avg
48.96
200-Day Avg
54.71
Revenue (TTM)
$621.87M
Revenue Growth (Qtr YoY)
314.6%
Profit Margin
-15%
Operating Margin (TTM)
47.1%
Beta
0.41
Volume
1.93M
30-Day Avg Volume
4.11M
CEO
Roger A. Jeffs
Employees
216
IPO Date
Jul 26, 2018

LQDA on X: what traders are saying

  • Marty Chargin @MartyChargin · Nov 13, 2026

    $LQDA ... Liquidia Technologies assumed with Buy and $76 price target at H.C. Wainwright (58.12) Analyst Matthew Caufield said, "Main reasons we like Liquidia's next YUTREPIA chapter following UTHR settlement. (1) We highlight that the October 2026 settlement with United…

  • Marc Lehman @markflowchatter · Nov 11, 2026

    $LQDA upgraded to Strong Buy $77 price tgt at RAYMOND JAMES

  • Marty Chargin @MartyChargin · Nov 10, 2026

    @jollie20015 @monaco_biotech $LQDA ... I was just playin...its all good...

  • Marty Chargin @MartyChargin · Nov 10, 2026

    @jollie20015 @monaco_biotech $LQDA ... listening to the call... SSSHHH??? ... https://t.co/7PO5d9070c

  • Marty Chargin @MartyChargin · Nov 10, 2026

    @monaco_biotech $LQDA ... I hear ya! .. we have seen some wild swings with earnings reports recently... I am not listening to the call... but the management team must be setting things straight as it is at $49 now...

  • Marty Chargin @MartyChargin · Nov 10, 2026

    @monaco_biotech $LQDA ... Yo Monaco ... that sucker was down big... and reversed higher ... 70,000 shares traded.... https://t.co/mfnp3znoMh

LQDA analyst rating & price target

8 analysts rate LQDA Buy on consensus.

2Strong Buy
4Buy
2Hold
0Sell
0Strong Sell

Consensus price target: $60.75 (+5.82% upside from $57.41)

Recent LQDA insider transactions

InsiderDateTransactionSharesValue
Boyle Dana
Chief Accounting Officer
Oct 26, 2026Sale1,581$68.28K
Adair Jason
Chief Business Officer
Oct 26, 2026Sale688$29.71K
Bloch Stephen M
director
Oct 5, 2026Sale235,477$6.39M
Krepp Sarah
Chief Human Resource Officer
Sep 1, 2026Sale274$18.57K
Rielly-Gauvin Katherine
director
Aug 20, 2026Sale18,393$1.33M

Liquidia Technologies Inc annual revenue & net income

Fiscal yearRevenueRevenue YoYNet income
2025$158.32M+1031.18%$-68.92M
2024$14M-19.97%$-130.39M
2023$17.49M+9.75%$-78.5M

Latest LQDA news

Stock data for LQDA: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics